Firm’s virus-killing nanomedicine technology, TheraCour, will be implemented.

NanoViricides signed a CRADA with the Walter Reed Army Institute of Research (WRAIR). The joint R&D effort will focus on creating new treatments for dengue fever using NanoViricides’ virus-killing nanomedicine technology.

“This collaboration will leverage Walter Reed’s extensive experience in dengue fever research with our unique nanoviricide™ technology platform for creating antiviral medications,” says president, Anil Diwan.

The company’s TheraCour technologies are used to develop nanotechnology-based targeted antiviral therapeutics.  

Previous articleAlteon and Oxis Expand Licensing Deal
Next articleScientists Discover Link Between Fumarate Hydratase and Renal Cancer